New powdered plasma shows promise in early safety trial

NCT ID NCT05629338

Completed Disease control Sponsor: Velico Medical Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tested the safety of a new spray-dried plasma product called FrontlineODP in 24 healthy volunteers. Participants received increasing doses (1 to 4 units) to see if it causes side effects. The goal is to develop a shelf-stable plasma that can be stored at room temperature for emergency bleeding situations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Spray-dried plasma (FrontlineODP)
What this could lead to: If safe, this could lead to a shelf-stable plasma product for treating bleeding in emergencies, especially where fresh plasma is unavailable.
What could go wrong: This is a very early Phase 1 safety study in only 24 healthy people, not patients. It does not test effectiveness, and side effects may still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COAGULOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

blood coagulation disease Hemorrhage vascular hemostatic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COAGULOPATHY HEMORRHAGE

Contacts and locations

Locations

Hoxworth Blood Center

Cincinnati, Ohio, 45267-0055, United States
Spaulding Clinical Research LLC

West Bend, Wisconsin, 53095, United States
Versiti Blood Center of Wisconsin

Milwaukee, Wisconsin, 53233, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.